SCHEMBL315539

SCHEMBL315539

O[C@@H]1[C@@H](O)[C@H](Oc2ccc(-c3ccnc(F)c3)nc2Cl)SC[C@H]1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.36
MINK1 Q8N4C8 4/20 0.36
TNIK Q9UKE5 4/20 0.36
AAK1 Q2M2I8 4/20 0.35
KMO O15229 5/20 0.33
CIT O14578 1/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
DAPK1 P53355 1/20 0.33
MAP2K1 Q02750 1/20 0.33
PKN2 Q16513 1/20 0.33
TLK2 Q86UE8 1/20 0.33
HIPK4 Q8NE63 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MYLK2 Q9H1R3 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
BMP2K Q9NSY1 1/20 0.33
STK39 Q9UEW8 1/20 0.33
TLK1 Q9UKI8 1/20 0.33
MTOR P42345 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL315540 1.00 MAP4K4 (0.36) MAP4K4MINK1TNIKAAK1KMO
SCHEMBL314927 0.89 MAP4K4 (0.37) MAP4K4MINK1TNIKAAK1KMO
SCHEMBL314926 0.89 MAP4K4 (0.37) MAP4K4MINK1TNIKAAK1KMO
SCHEMBL314722 0.85 MAPT (0.33) KMOJAK2MAP2K1MTORMAPT
SCHEMBL314723 0.85 MAPT (0.33) KMOJAK2MAP2K1MTORMAPT
SCHEMBL316562 0.85 MAP2K3 (0.32)
SCHEMBL316561 0.85 MAP2K3 (0.32)
SCHEMBL313709 0.82 IDO1 (0.35) MAP4K4MINK1TNIKMTORMAPT
SCHEMBL2411021 0.82 DYRK1A (0.38) AAK1KMOGBA1UGCGGBA2
SCHEMBL2411023 0.82 DYRK1A (0.38) AAK1KMOGBA1UGCGGBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093394-B2 Derivatives of 5-thioxylopyranose and use of same for treatment LABORATOIRES FOURNIER S.A. (FR) 2012-01-10 US disclosed
EP-2066683-B1 DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT FOURNIER LAB SA (FR) 2010-11-03 EP disclosed
US-20090182013-A1 Derivatives of 5-Thioxylopyranose and Use of Same for Treatment LABORATOIRES FOURNIER S.A. (FR) 2009-07-16 US disclosed
EP-2066683-A1 DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT LABORATOIRES FOURNIER SA (FR) 2009-06-10 EP disclosed
WO-2008037922-A1 DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT LABORATOIRES FOURNIER S.A. (FR) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182013-A1 Derivatives of 5-Thioxylopyranose and Use of Same for Treatment TPMT, PNPO, PPOX MAP4K4 4447/4885MINK1 4277/4885TNIK 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.